Financial News Feed

Stronger Sell Today XLRN ranks #5057 as SELL CANDIDATE. Weaker Sell
Today XLRN ranks #5057 as SELL CANDIDATE.

XLRN stock Acceleron Pharma Inc.

XLRN stock
Acceleron Pharma Inc.

Watching the technicals on shares of Acceleron Pharma (XLRN), we have recently noted that the Chaikin Oscillator is above zero. Traders may be following the stock over the next few trading periods to ... Read more
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intend... Read more
Investors sentiment decreased to 1.03 in 2018 Q3. Its down 0.44, from 1.47 in 2018Q2. It worsened, as 20 investors sold Acceleron Pharma Inc. shares while 43 reduced holdings. 22 funds opened position... Read more
Stock market investors might be taking note of recent trends. Many investors will be digging deep into the numbers to try and spot potential breakouts. Following the numbers for Acceleron Pharma Inc. ... Read more
Acceleron Pharma Inc. today announced that it has priced an underwritten public offering of 5,348,838 shares of common stock at a price to the public of $43.00 per share for gross proceeds of $230.0 m... Read more
Acceleron Pharma Inc. (XLRN) had a rough trading day for Tuesday January 15 as shares tumbled 5.43%, or a loss of $-2.52 per share, to close at $43.92. After opening the day at $43.94, shares of... Read more
The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Acceleron ... Read more
Investors may be following the shorter-term MACD oscillator on shares of Acceleron Pharma (XLRN). The signal is currently pointing to a Sell. The MACD is generally used to measure bullish or bearish p... Read more
Sell-side equity analysts are typically working super hard to create realistic target prices for stocks that they cover. After a recent market scan, we can see that Acceleron Pharma Inc. (NASDAQ:XLRN)... Read more
Acceleron Pharma (XLRN) launches a $200M public offering of common stock. Price, volume and terms have yet to be announced. Shares are up 1% after hours.... Read more
The EBITDA Yield for George Weston Limited (TSX:WN) is 0.092388. The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a company’s earnings ... Read more
Investors may be taking a closer look at some different trading signals on shares of Acceleron Pharma (XLRN). After a recent check, we can see that the current 20-day moving average vs price signal is... Read more
Investors may be watching indicator signals on shares of Acceleron Pharma (XLRN). After a recent look, we have noted that the beta research opinion is currently Sell. This signal uses a system combini... Read more
The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Acceleron ... Read more
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and... Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank